<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895011</url>
  </required_header>
  <id_info>
    <org_study_id>TA-303</org_study_id>
    <nct_id>NCT00895011</nct_id>
    <nct_alias>NCT01171001</nct_alias>
  </id_info>
  <brief_title>Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the safety and efficacy of two doses of avanafil
      in the treatment of adult males for erectile dysfunction following bilateral nerve-sparing
      radical prostatectomy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Percentage of Sexual Attempts in Which Subjects Are Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Data presented as mean change from baseline in the percentage of Yes responses to Sexual Encounter Profile (SEP) diary question 3 &quot;Did your erection last long enough for you to have successful intercourse?&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Change in Percentage of Sexual Attempts in Which Subjects Are Able to Insert the Penis Into the Partner's Vagina</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Data presented as mean change from baseline in the percentage of Yes responses to Sexual Encounter Profile (SEP) diary question 2 &quot;Were you able to insert your penis into your partner's vagina?&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in International Index of Erectile Function - Erectile Function Domain (IIEF-EF) Score</measure>
    <time_frame>Baseline, End of Treatment (up to 12 weeks)</time_frame>
    <description>Questionnaire assesses subject's evaluation of erectile function over the previous 4-week period. Total scores from questions 1-5 &amp; 15 range from 1 to 30. A higher score indicates better erectile function.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">298</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Avanafil 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Avanafil 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One dose 30 minutes prior to initiation of sexual activity</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avanafil</intervention_name>
    <description>One dose 30 minutes prior to initiation of sexual activity</description>
    <arm_group_label>Avanafil 100 mg</arm_group_label>
    <other_name>TA-1790</other_name>
    <other_name>Stendra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avanafil</intervention_name>
    <description>One dose 30 minutes prior to initiation of sexual activity</description>
    <arm_group_label>Avanafil 200 mg</arm_group_label>
    <other_name>TA-1790</other_name>
    <other_name>Stendra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males ≥ 18 years and ≤ 70 years;

          -  Have a history of erectile dysfunction of at least 6 months duration following
             bilateral nerve-sparing retropubic radical prostatectomy;

          -  Have a PSA level consistent with the absence of prostate cancer;

          -  Have a history of sexual potency prior to radical prostatectomy without requiring
             medical therapy;

          -  Be in a monogamous, heterosexual relationship with their current partner for at least
             3 months;

          -  Provide written informed consent;

          -  Agree to make at least 4 attempts at intercourse per month;

          -  Agree not to use any other treatments for erectile dysfunction;

          -  Be willing and able to comply with all study requirements (including scheduled study
             visits, treatment plans, laboratory tests and other study procedures).

        Exclusion Criteria

          -  Allergy or hypersensitivity to PDE5 inhibitors or any of the components of these drug
             products;

          -  History of dose-limiting AEs during prior treatment with a PDE5 inhibitor or
             discontinued use of a PDE5 inhibitor due to lack of efficacy at the highest tolerated
             dose;

          -  Concomitant use of one or more of the following medications:

               -  Any nitrate, trazodone, itraconazole, ketoconazole, erythromycin, or cimetidine;

               -  Other prescription or OTC drugs that are known to interfere with metabolism by
                  the CYP 3A4 enzyme;

               -  If receiving hormone replacement therapy (including thyroid supplementation),
                  dose that has not been stable for at least 3 months;

               -  If treated with an alpha blocker, dose that has not been stable for at least 14
                  days;

          -  Erectile dysfunction as a consequence of advanced neurologic disease, spinal cord
             injury, or diabetes;

          -  History of severe erectile dysfunction requiring medical therapy prior to bilateral
             nerve-sparing radical prostatectomy;

          -  History of previous pelvic surgery, brachytherapy, or cryotherapy of the prostate;

          -  Sexual partner who is under 18 years of age, pregnant, intends to become pregnant
             during the course of the study, is breastfeeding, has dyspareunia or other gynecologic
             conditions or other major medical conditions that would interfere with sexual activity
             or would have difficulty complying with study requirements;

          -  Uncontrolled hypertension;

          -  Hypotension;

          -  Orthostatic hypotension;

          -  Myocardial infarction, stroke, life-threatening arrhythmia or coronary
             revascularization within the past 6 months;

          -  Unstable angina, angina with sexual intercourse, or congestive heart failure &gt; NYHA
             Class II;

          -  History or ECG evidence of any high-risk arrhythmia or clinically significant ECG;

          -  Hypertrophic, obstructive, or other clinically significant cardiomyopathy, moderate or
             severe cardiac valvular disease;

          -  Type 1 or type 2 diabetes, history of use of any antidiabetic medication;

          -  Clinically evident penile lesions, abrasions, anatomical deformities such as penile
             fibrosis, Peyronie's disease, penile implants, urinary tract or bladder infection, or
             sexually transmissible disease that the investigator deems to be clinically
             significant;

          -  Condition(s) predisposing to priapism, such as sickle cell disease , multiple myeloma,
             or leukemia;

          -  Any malignancy other than carcinoma of the prostate (except basal cell carcinoma or
             squamous cell carcinoma of the skin);

          -  Prior use of, or likely to require radiotherapy, chemotherapy, androgen deprivation
             therapy, cryotherapy, non-nerve-sparing surgery, and/or bladder or penile surgery
             during the study;

          -  Evidence of significant hepatic impairment;

          -  On dialysis, or history of renal transplantation;

          -  Untreated hypogonadism or low serum total testosterone;

          -  Abnormal laboratory value(s) judged to be clinically significant by the investigator;

          -  Positive STD screen (syphilis, gonorrhea, or chlamydia);

          -  Positive for HIV, HCV Ab, or HBsAg at screening;

          -  History or current drug, alcohol, or substance abuse;

          -  Positive urine drug screen;

          -  Positive breath alcohol test;

          -  Retinitis pigmentosa or nonarteritic anterior ischemic optic neuropathy;

          -  Use of any treatment or device for treatment of erectile dysfunction;

          -  Use of any other investigational medication or device for any indication within 30
             days prior to enrollment or at any time during this study;

          -  Previous participation in any other investigational study of avanafil;

          -  Any history of bipolar disorder or psychosis, greater than one lifetime episode of
             major depression, current depression of moderate or greater severity or antidepressant
             use that has not been stable for at least 3 months;

          -  Involvement in the planning and conduct of the study on the part of subject or
             partner;

          -  Evidence of any clinically significant medical, psychiatric, social or other condition
             by history, physical examination or laboratory studies that, in the opinion of the
             investigator, would contraindicate the administration of study medications, affect
             compliance, interfere with study evaluations, limit study participation,
             contraindicate sexual activity or confound the interpretation of study results.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Mulhall, MD</last_name>
    <role>Study Director</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parker</city>
        <state>Colorado</state>
        <zip>80134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trinity</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jamaica Plain</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlottesville,</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2009</study_first_submitted>
  <study_first_submitted_qc>May 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2009</study_first_posted>
  <results_first_submitted>May 25, 2012</results_first_submitted>
  <results_first_submitted_qc>May 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 28, 2012</results_first_posted>
  <disposition_first_submitted>June 6, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 6, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 21, 2011</disposition_first_posted>
  <last_update_submitted>September 14, 2012</last_update_submitted>
  <last_update_submitted_qc>September 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile Dysfunction</keyword>
  <keyword>E.D.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subject recruitment occurred at US investigative sites between April 2009 and December 2010.</recruitment_details>
      <pre_assignment_details>Subjects meeting the initial eligibility criteria completed a 4-week non-treatment run-in period during which information on each attempt at intercourse was recorded. At the end of the run-in, subjects meeting the randomization criteria were eligible for assignment to one of the treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo 30 minutes orally prior to initiation of sexual activity</description>
        </group>
        <group group_id="P2">
          <title>Avanafil 100 mg</title>
          <description>avanafil 100 mg 30 minutes orally prior to initiation of sexual activity</description>
        </group>
        <group group_id="P3">
          <title>Avanafil 200 mg</title>
          <description>avanafil 200 mg 30 minutes orally prior to initiation of sexual activity</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>schedule conflict</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>Avanafil 100 mg</title>
        </group>
        <group group_id="B3">
          <title>Avanafil 200 mg</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="99"/>
            <count group_id="B4" value="298"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="5.87"/>
                    <measurement group_id="B2" value="58.9" spread="5.88"/>
                    <measurement group_id="B3" value="57.7" spread="6.60"/>
                    <measurement group_id="B4" value="58.4" spread="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Percentage of Sexual Attempts in Which Subjects Are Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse</title>
        <description>Data presented as mean change from baseline in the percentage of Yes responses to Sexual Encounter Profile (SEP) diary question 3 &quot;Did your erection last long enough for you to have successful intercourse?&quot;</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Number of participants analyzed represents the Intent-to-Treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placeb 30 minutes orally prior to initiation of sexual activity</description>
          </group>
          <group group_id="O2">
            <title>Avanafil 100 mg</title>
            <description>avanafil 100 mg 30 minutes orally prior to initiation of sexual activity</description>
          </group>
          <group group_id="O3">
            <title>Avanafil 200 mg</title>
            <description>avanafil 200 mg 30 minutes orally prior to initiation of sexual activity</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Sexual Attempts in Which Subjects Are Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse</title>
          <description>Data presented as mean change from baseline in the percentage of Yes responses to Sexual Encounter Profile (SEP) diary question 3 &quot;Did your erection last long enough for you to have successful intercourse?&quot;</description>
          <population>Number of participants analyzed represents the Intent-to-Treat population.</population>
          <units>percentage of sexual attempts</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="3.42"/>
                    <measurement group_id="O2" value="28.0" spread="3.54"/>
                    <measurement group_id="O3" value="29.4" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Change in Percentage of Sexual Attempts in Which Subjects Are Able to Insert the Penis Into the Partner's Vagina</title>
        <description>Data presented as mean change from baseline in the percentage of Yes responses to Sexual Encounter Profile (SEP) diary question 2 &quot;Were you able to insert your penis into your partner's vagina?&quot;</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Number of participants analyzed represents the Intent-to-Treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo 30 minutes orally prior to initiation of sexual activity</description>
          </group>
          <group group_id="O2">
            <title>Avanafil 100 mg</title>
            <description>avanafil 100 mg 30 minutes orally prior to initiation of sexual activity</description>
          </group>
          <group group_id="O3">
            <title>Avanafil 200 mg</title>
            <description>avanafil 200 mg 30 minutes orally prior to initiation of sexual activity</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Percentage of Sexual Attempts in Which Subjects Are Able to Insert the Penis Into the Partner's Vagina</title>
          <description>Data presented as mean change from baseline in the percentage of Yes responses to Sexual Encounter Profile (SEP) diary question 2 &quot;Were you able to insert your penis into your partner's vagina?&quot;</description>
          <population>Number of participants analyzed represents the Intent-to-Treat population.</population>
          <units>Percentage of Sexual Attempts</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="3.68"/>
                    <measurement group_id="O2" value="22.3" spread="3.66"/>
                    <measurement group_id="O3" value="27.7" spread="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in International Index of Erectile Function - Erectile Function Domain (IIEF-EF) Score</title>
        <description>Questionnaire assesses subject's evaluation of erectile function over the previous 4-week period. Total scores from questions 1-5 &amp; 15 range from 1 to 30. A higher score indicates better erectile function.</description>
        <time_frame>Baseline, End of Treatment (up to 12 weeks)</time_frame>
        <population>Number of participants analyzed represents the Intent-to-Treat population. For dropouts or missing data, the last observation carried forward convention was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo 30 minutes orally prior to initiation of sexual activity</description>
          </group>
          <group group_id="O2">
            <title>Avanafil 100 mg</title>
            <description>avanafil 100 mg 30 minutes orally prior to initiation of sexual activity</description>
          </group>
          <group group_id="O3">
            <title>Avanafil 200 mg</title>
            <description>avanafil 200 mg 30 minutes orally prior to initiation of sexual activity</description>
          </group>
        </group_list>
        <measure>
          <title>Change in International Index of Erectile Function - Erectile Function Domain (IIEF-EF) Score</title>
          <description>Questionnaire assesses subject's evaluation of erectile function over the previous 4-week period. Total scores from questions 1-5 &amp; 15 range from 1 to 30. A higher score indicates better erectile function.</description>
          <population>Number of participants analyzed represents the Intent-to-Treat population. For dropouts or missing data, the last observation carried forward convention was used.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.16"/>
                    <measurement group_id="O2" value="4.7" spread="1.18"/>
                    <measurement group_id="O3" value="6.2" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE reporting began when the subject provided written informed consent and extended until 28 calendar days after the last dose of the investigational product was administered, or until the subject was discontinued from the study, whichever was later.</time_frame>
      <desc>A treatment-emergent adverse event (TEAE) is an adverse event occurring on or after the first dose of study medication, or on or after the first dispensed date if missing, and prior to the last visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Avanafil 100 mg</title>
        </group>
        <group group_id="E3">
          <title>Avanafil 200 mg</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="19" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" events="35" subjects_affected="12" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="30" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" events="31" subjects_affected="10" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution &amp; PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wesley W Day, PhD</name_or_title>
      <organization>Vivus, Inc.</organization>
      <phone>650-934-5200</phone>
      <email>medaffairs@vivus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

